D. T. Huynh, Minh-Ngoc T. Le, V. D. Tran, Viet-Hung Tran, D. T. Pham
{"title":"Native Medicinal Plants (Moringa oleifera Lam, Brucea javanica (L.) Merr., Eclipta prostrata (L.), Callisia fragrans (Lindl.) Woodson, and Zingiber zerumbet (L.) Smith) in An Giang, Vietnam: A Preliminary Investigation for Rhabdomyosarcoma Treatments using in-vitro RD cell cytotoxicity test","authors":"D. T. Huynh, Minh-Ngoc T. Le, V. D. Tran, Viet-Hung Tran, D. T. Pham","doi":"10.35516/jjps.v16i4.1365","DOIUrl":null,"url":null,"abstract":"Cancer, one of the deadliest diseases worldwide, is projected to affect 30.2 million people by 2040. Among the various cancer types, rhabdomyosarcoma (RMS) is a unique tumor primarily impacting the muscular system of children. The current treatment for RMS has limited efficacy and numerous side effects, emphasizing the need for novel therapeutic approaches. This study investigates the potential treatment of the RMS cell line RD using extracts from five folklore-based medicinal plants in An Giang, Vietnam. The plants—Moringa oleifera Lam, Brucea javanica (L.) Merr., Eclipta prostrata (L.), Callisia fragrans (Lindl.) Woodson, and Zingiber zerumbet (L.) Smith—were extracted and fractionated using three solvents: ether, ethanol, and water. These fractions underwent phytochemical screening and cytotoxicity testing on the in-vitro RMS cell line RD. The results indicate that the ether fraction of Eclipta prostrata (L.) and the ether and ethanol fractions of Zingiber zerumbet (L.) Smith exhibit moderate cytotoxic effects on RD cell lines, with IC50 values of 37.08 ± 1.23 µg/mL, 23.15 ± 1.17 µg/mL, and 45.63 ± 2.39 µg/mL, respectively. These findings provide preliminary data for further in-depth research into the anticancer properties of these plants, which are widely grown in the South of Vietnam.","PeriodicalId":14719,"journal":{"name":"Jordan Journal of Pharmaceutical Sciences","volume":"25 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jordan Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35516/jjps.v16i4.1365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer, one of the deadliest diseases worldwide, is projected to affect 30.2 million people by 2040. Among the various cancer types, rhabdomyosarcoma (RMS) is a unique tumor primarily impacting the muscular system of children. The current treatment for RMS has limited efficacy and numerous side effects, emphasizing the need for novel therapeutic approaches. This study investigates the potential treatment of the RMS cell line RD using extracts from five folklore-based medicinal plants in An Giang, Vietnam. The plants—Moringa oleifera Lam, Brucea javanica (L.) Merr., Eclipta prostrata (L.), Callisia fragrans (Lindl.) Woodson, and Zingiber zerumbet (L.) Smith—were extracted and fractionated using three solvents: ether, ethanol, and water. These fractions underwent phytochemical screening and cytotoxicity testing on the in-vitro RMS cell line RD. The results indicate that the ether fraction of Eclipta prostrata (L.) and the ether and ethanol fractions of Zingiber zerumbet (L.) Smith exhibit moderate cytotoxic effects on RD cell lines, with IC50 values of 37.08 ± 1.23 µg/mL, 23.15 ± 1.17 µg/mL, and 45.63 ± 2.39 µg/mL, respectively. These findings provide preliminary data for further in-depth research into the anticancer properties of these plants, which are widely grown in the South of Vietnam.
期刊介绍:
The Jordan Journal of Pharmaceutical Sciences (JJPS) is a scientific, bi-annual, peer-reviewed publication that will focus on current topics of interest to the pharmaceutical community at large. Although the JJPS is intended to be of interest to pharmaceutical scientists, other healthy workers, and manufacturing processors will also find it most interesting and informative. Papers will cover basic pharmaceutical and applied research, scientific commentaries, as well as views, reviews. Topics on products will include manufacturing process, quality control, pharmaceutical engineering, pharmaceutical technology, and philosophies on all aspects of pharmaceutical sciences. The editorial advisory board would like to place an emphasis on new and innovative methods, technologies, and techniques for the pharmaceutical industry. The reader will find a broad range of important topics in this first issue.